Literature DB >> 28411107

Pulmonary hypertension due to left heart disease.

Emmanuelle Berthelot1, Minh Tam Bailly2, Safwane El Hatimi2, Ingrid Robard3, Hatem Rezgui3, Amir Bouchachi3, David Montani4, Olivier Sitbon4, Denis Chemla5, Patrick Assayag2.   

Abstract

Pulmonary hypertension due to left heart disease, also known as group 2 pulmonary hypertension according to the European Society of Cardiology/European Respiratory Society classification, is the most common cause of pulmonary hypertension. In patients with left heart disease, the development of pulmonary hypertension favours right heart dysfunction, which has a major impact on disease severity and outcome. Over the past few years, this condition has been considered more frequently. However, epidemiological studies of group 2 pulmonary hypertension are less exhaustive than studies of other causes of pulmonary hypertension. In group 2 patients, pulmonary hypertension may be caused by an isolated increase in left-sided filling pressures or by a combination of this condition with increased pulmonary vascular resistance, with an abnormally high pressure gradient between arteries and pulmonary veins. A better understanding of the conditions underlying pulmonary hypertension is of key importance to establish a comprehensive diagnosis, leading to an adapted treatment to reduce heart failure morbidity and mortality. In this review, epidemiology, mechanisms and diagnostic approaches are reviewed; then, treatment options and future approaches are considered.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Cardiopathie gauche; Hypertension pulmonaire; Left heart disease; Management; Pathophysiology; Physiopathologie; Prise en charge; Pulmonary hypertension

Mesh:

Year:  2017        PMID: 28411107     DOI: 10.1016/j.acvd.2017.01.010

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  3 in total

1.  Distinct plasma gradients of microRNA-204 in the pulmonary circulation of patients suffering from WHO Groups I and II pulmonary hypertension.

Authors:  Leonard E Estephan; Michael V Genuardi; Chad M Kosanovich; Michael G Risbano; Yingze Zhang; Nancy Petro; Annie Watson; Yassmin Al Aaraj; John C Sembrat; Mauricio Rojas; Dmitry A Goncharov; Marc A Simon; Elena A Goncharova; Anjali Vaidya; Akaya Smith; Jeremy Mazurek; Yuchi Han; Stephen Y Chan
Journal:  Pulm Circ       Date:  2019 Apr-Jun       Impact factor: 3.017

2.  Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics.

Authors:  Abdulla Ahmed; Salaheldin Ahmed; Mattias Arvidsson; Habib Bouzina; Jakob Lundgren; Göran Rådegran
Journal:  ESC Heart Fail       Date:  2019-12-19

3.  Prognostic Value of Right Ventricular Cardiac Power Output at Rest in Patients with Advanced Heart Failure.

Authors:  Omer Yildiz; Cemal Deniz Yenigun
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.